Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arch Therapeutics (ARTH)
OTHER OTC:ARTH
Arch Therapeutics (ARTH) Stock Price & Analysis
160 Followers
ARTH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.39 - $18.00
Previous Close$0.96
Volume1.98K
Average Volume (3M)2.73K
Market Cap
$550.03K
Enterprise Value$327.49K
Total Cash (Recent Filing)$205.85K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.44
Next Earnings
May 14, 2019EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.84
Shares Outstanding4,444,363
10 Day Avg. Volume2,291
30 Day Avg. Volume2,729
Standard Deviation0.76
R-Squared0.06
Alpha-0.00399
Financial Highlights & Ratios
Price to Book (P/B)-0.44
Price to Sales (P/S)106.85
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio3.30
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.99
Enterprise Value/Gross Profit-134.27
Enterprise Value/Ebitda-0.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Arch Therapeutics News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARTH FAQ
What was Arch Therapeutics’s price range in the past 12 months?
Arch Therapeutics lowest stock price was $0.39 and its highest was $18.00 in the past 12 months.
What is Arch Therapeutics’s market cap?
Currently, no data Available
When is Arch Therapeutics’s upcoming earnings report date?
Arch Therapeutics’s upcoming earnings report date is May 14, 2019 which is 1880 days ago.
How were Arch Therapeutics’s earnings last quarter?
Arch Therapeutics released its earnings results on Feb 01, 2019. The company reported -$4 earnings per share for the quarter, missing the consensus estimate of N/A by -$4.
Is Arch Therapeutics overvalued?
According to Wall Street analysts Arch Therapeutics’s price is currently Overvalued.
Does Arch Therapeutics pay dividends?
Arch Therapeutics does not currently pay dividends.
What is Arch Therapeutics’s EPS estimate?
Arch Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arch Therapeutics have?
Arch Therapeutics has 555,562 shares outstanding.
What happened to Arch Therapeutics’s price movement after its last earnings report?
Arch Therapeutics reported an EPS of -$4 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Arch Therapeutics?
Currently, no hedge funds are holding shares in ARTH
---
Arch Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.17%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.31%
Trailing 12-Months
Company Description
Arch Therapeutics
Arch Therapeutics, Inc. is a development stage biotechnology company, which engages in the development and provision of hemostasis and sealant technology platform. Its product candidates include AC5 Devices, which designed to achieve hemostasis during surgical, wound, and interventional care. The company was founded by Rutledge Ellis-Behnke and Terrence W. Norchi on September 16, 2009 and is headquartered in Framingham, MA.
---
Technical Analysis
---